Mar 27, 2014
As reported by POLITICO, Food and Drug Administration Commissioner Margaret Hamburg reinforced the FDA’s stance on the labeling of products containing biotechnology in a House Appropriations subcommittee meeting this morning. FDA, according to Hamburg, supports voluntary labeling, but opposed mandatory labeling.
"Mandatory labeling really is appropriate when there is a fault claim,” testified Hamburg. “The fact that a product contains GE ingredients does not change the material content of the product.”
Hamburg went on to reiterate that in more than 20 years of commercialized biotech traits, the FDA has yet to find evidence of food safety risks.